Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Translational Cancer Mechanisms and Therapy

IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody

Ji Li, Ryan Ybarra, Judy Mak, Aurelie Herault, Patricia De Almeida, Alfonso Arrazate, James Ziai, Klara Totpal, Melissa R. Junttila, Kevin B. Walsh and Teemu T. Junttila
Ji Li
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Ybarra
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judy Mak
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurelie Herault
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia De Almeida
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfonso Arrazate
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Ziai
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klara Totpal
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa R. Junttila
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin B. Walsh
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: junttila.teemu@gene.com walsh.kevin@gene.com junttila.melissa@gene.com
Teemu T. Junttila
Genentech, Inc. 1, South San Francisco, California 94080.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: junttila.teemu@gene.com walsh.kevin@gene.com junttila.melissa@gene.com
DOI: 10.1158/1078-0432.CCR-18-1139 Published December 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: June 2018 to February 2021

AbstractFull-text HTMLPDF
Total575710792161

Cited By

Article Information

Volume 24, Issue 24, pp. 6447-6458

DOI 
https://doi.org/10.1158/1078-0432.CCR-18-1139
PubMed 
29950350

Published By 
American Association for Cancer Research
Print ISSN 
1078-0432
Online ISSN 
1557-3265
History 
  • Received April 12, 2018
  • Revision received May 31, 2018
  • Accepted June 22, 2018
  • Published first June 27, 2018.

Article Versions

  • Previous version (June 27, 2018 - 05:51).
  • Previous version (September 28, 2018 - 06:40).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2018 American Association for Cancer Research.

Author Information

  1. Ji Li,
  2. Ryan Ybarra,
  3. Judy Mak,
  4. Aurelie Herault,
  5. Patricia De Almeida,
  6. Alfonso Arrazate,
  7. James Ziai,
  8. Klara Totpal,
  9. Melissa R. Junttila,
  10. Kevin B. Walsh*, and
  11. Teemu T. Junttila*
  1. Genentech, Inc. 1, South San Francisco, California 94080.
  1. ↵*Corresponding Authors:
    Teemu T. Junttila, Genentech Inc. 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-1000; E-mail: junttila.teemu{at}gene.com; Kevin B. Walsh, walsh.kevin{at}gene.com; and Melissa R. Junttila, junttila.melissa{at}gene.com
View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 24 (24)
December 2018
Volume 24, Issue 24
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody
Ji Li, Ryan Ybarra, Judy Mak, Aurelie Herault, Patricia De Almeida, Alfonso Arrazate, James Ziai, Klara Totpal, Melissa R. Junttila, Kevin B. Walsh and Teemu T. Junttila
Clin Cancer Res December 15 2018 (24) (24) 6447-6458; DOI: 10.1158/1078-0432.CCR-18-1139

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody
Ji Li, Ryan Ybarra, Judy Mak, Aurelie Herault, Patricia De Almeida, Alfonso Arrazate, James Ziai, Klara Totpal, Melissa R. Junttila, Kevin B. Walsh and Teemu T. Junttila
Clin Cancer Res December 15 2018 (24) (24) 6447-6458; DOI: 10.1158/1078-0432.CCR-18-1139
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • High IFN Signaling and Resistance to CDK4/6 Inhibitors
  • CD1d-Specific Vγ9Vδ2-T Cell Engager in CLL
  • The Genomics of 9/11 World Trade Center Myelomas
Show more Translational Cancer Mechanisms and Therapy
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement